Clinical Trials Browser

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

Clinical Trials

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

FAPI PET RDRC

Sapu003 in Advanced mTOR-sensitive Solid Tumors

NEUK203-13

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

KinLET

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

LANTana

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET

PRRT-PARPi

HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Study of rSIFN-co for Patients With Advanced Solid Tumors

Lumed

PARLuNET

Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

LuPARP

Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors

DUET-1

Study of Everolimus (RAD001) in Combination With Lenalidomide

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1

Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors

A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression

Study of JS001 in Patients With Advanced Neuroendocrine Tumors

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors

Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases

Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors

177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors

68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)

Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease

mIBG

ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid